Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy in Relapsed/Refractory AML
NCT03473457Phase 1Terminated
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD38 chimeric antigen receptor T-cell, anti-CD33 CAR-T, Anti-CD123 CAR-T, CD133-CAR T cells and anti-muc1 car-t cells in acute myeloid leukemia (AML), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Adverse events that Are related to treatment at 2 years. Started Apr 2018; status: terminated.
02
Drugs
anti-CD38 chimeric antigen receptor T-cellanti-CD33 CAR-TAnti-CD123 CAR-TCD133-CAR T cellsanti-muc1 car-t cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03473457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473457.